Skip to main content

Table 2 Base-case probabilistic cost-effectiveness results: lifetime average costs and QALYs per woman

From: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation

Model lifetime results No screening MMS USS
Costs £179 £598 £824
(95% confidence interval) (£137 to £242) (£434 to £758) (£566 to £1154)
 Incremental costs £419 £646
(95% confidence interval) (£255 to £578) (£386 to £973)
 QALYs 14.290 14.357 14.297
(95% confidence interval) (5.159 to 15.907) (5.168 to 15.959) (5.147 to 15.926)
 Incremental QALYs 0.047 0.007
(95% confidence interval) (0.002 to 0.088) (–0.042 to 0.049)
 ICER per QALY £8864 vs no screening Dominated by MMS
(95% confidence interval) (£2600 to £51,576)
 Life years 24.660 24.803 24.729
(95% confidence interval) (24.543 to 24.741) (24.668 to 24.872) (24.554 to 24.822)
 Incremental life years 0.142 0.069
(95% confidence interval) (0.03 to 0.24) (–0.07 to 0.17)
 Ovarian cancer deaths 3.19% 1.41% 2.35%
(95% confidence interval) (1.98% to 5.17%) (0.56% to 3.46%) (1.06% to 5.21%)
 Incremental OC deaths –1.77% –0.83%
(95% confidence interval) (–3.38% to –0.19%) (–2.39% to 1.26%)
Model 11-year results No screening MMS USS
 Costs £58 £510 £612
(95% confidence interval) (£49 to £67) (£350 to £660) (£399 to £886)
 QALYs 8.250 8.247 8.239
(95% confidence interval) (2.823 to 9.163) (2.820 to 9.162) (2.801 to 9.157)
 Life years 11.093 11.093 11.093
(95% confidence interval) (11.090 to 11.096) (11.086 to 11.098) (11.089 to 11.097)
 Cancers diagnosed 0.59% 0.65% 0.61%
(95% confidence interval) (0.55% to 0.64%) (0.58% to 0.72%) (0.55% to 0.69%)
 Ovarian cancer deaths 0.34% 0.31% 0.33%
(95% confidence interval) (0.29% to 0.41%) (0.21% to 0.44%) (0.26% to 0.41%)
Observed trial results No screening MMS USS
 Cancers diagnosed 0.62% 0.67% 0.62%
(95% confidence interval) (0.58% to 0.67%) (0.60% to 0.74%) (0.56% to 0.69%)
 Ovarian cancer deaths 0.34% 0.29% 0.30%
(95% confidence interval) (0.31% to 0.38%) (0.25% to 0.34%) (0.26% to 0.36%)
  1. OC ovarian cancer, QALYs quality-adjusted life years
  2. Costs and QALYs are discounted, life years are not. Incremental values are relative to no screening